Clinical Trial Update: An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study to establish the maximum tolerated dose of E7389 liposomal formulation in patients with solid tumors completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• E7389 Liposomal Formulation (eribulin liposomal formulation)

Snippet

Sponsor: Eisai Limited | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2019-07-23